![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/biolinerx-announces-clinical-trial-agreement-with-st-jude-childrens-research-hospital-inc-to-evaluate-motixafortide-for-cd34-hematopoietic-stem-cell-hsc-mobilization-for-gene-therapy-applications-in-sickle-cell-disease-scd-302158612.html
https://www.prnewswire.com/news-releases/biolinerx-reports-first-quarter-2024-financial-results-and-recent-corporate-and-portfolio-updates-302156149.html
https://www.prnewswire.com/news-releases/biolinerx-to-report-first-quarter-2024-results-on-may-28-2024-302151919.html
https://www.prnewswire.com/news-releases/biolinerx-announces-receipt-of-nasdaq-minimum-bid-price-notification-302149239.html
https://www.prnewswire.com/news-releases/biolinerx-announces-poster-presentation-on-economic-model-data-for-aphexda-motixafortide-as-part-of-cd34-hematopoietic-stem-cell-mobilization-in-patients-with-multiple-myeloma-at-ispor-2024-302135166.html
https://www.prnewswire.com/news-releases/biolinerx-announces-poster-presentation-on-apheresis-center-efficiency-and-cxcr4-antagonists-including-aphexda-motixafortide-in-patients-with-multiple-myeloma-at-the-asfa-2024-annual-meeting-302118663.html
https://www.prnewswire.com/news-releases/biolinerx-accesses-second-tranche-of-20-million-under-previously-announced-40-million-non-dilutive-debt-financing-agreement-302113022.html
https://www.prnewswire.com/news-releases/biolinerx-announces-6-million-registered-direct-offering-302104494.html
https://www.prnewswire.com/news-releases/biolinerx-reports-2023-financial-results-and-recent-corporate-and-portfolio-updates-302099418.html